Literature DB >> 10951271

The membrane-associated protein pKe#192/MAP17 in human keratinocytes.

C Jaeger1, B M Schaefer, R Wallich, M D Kramer.   

Abstract

UNLABELLED: In order to isolate genes that are upregulated in human keratinocytes upon loss of cell/matrix contact, a subtractive cDNA library was constructed from dispase-treated versus untreated keratinocytes. Among the cloned cDNAs one was pKe#192 having an open reading frame of 411 bp. By database analysis pKe#192 was found to be identical with the gene "MAP17" previously isolated from human kidney. Kyte-Doolittle hydrophobicity analyzes showed a hydrophobic amino terminus of 13 amino acids, a transmembrane region and a 61 amino acid hydrophilic carboxy-terminus and two potential phosphorylation sites. In order to study regulation of pKe#192/MAP17 expression, RNA was extracted from resting human keratinocytes and from keratinocytes stimulated by dispase-induced detachment from the growth substratum. Reverse transcription polymerase chain reaction did not reveal specific mRNA in resting keratinocytes, whereas mRNA was detectable after detachment. For further characterization poly- and monoclonal antibodies were generated against a recombinant fusion protein. Immunohistologic studies using the mono- and polyclonal antibodies showed staining of the upper layers of the stratum granulosum in normal human epidermis. The staining was colocalized with involucrin. Immunhistologic staining of frozen sections derived from lesional skin of bullous pemphigoid und pemphigus vulgaris indicated that pKe#192/MAP17 was upregulated in the epidermis adjacent to the blister. Taken together, the data demonstrate that pKe#192/MAP17 is expressed in keratinocytes and may be involved in epidermal physiology and pathology. KEYWORDS: bullous diseases/differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951271     DOI: 10.1046/j.1523-1747.2000.00071.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  PDZK1-interacting protein 1 (PDZK1IP1) traps Smad4 protein and suppresses transforming growth factor-β (TGF-β) signaling.

Authors:  Souichi Ikeno; Naoko Nakano; Keigo Sano; Takashi Minowa; Wataru Sato; Ryosuke Akatsu; Nobuo Sakata; Nobutaka Hanagata; Makiko Fujii; Fumiko Itoh; Susumu Itoh
Journal:  J Biol Chem       Date:  2019-02-04       Impact factor: 5.157

2.  Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo.

Authors:  E Delabesse; S Ogilvy; M A Chapman; S G Piltz; B Gottgens; A R Green
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

3.  MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway.

Authors:  Qian Liang; Huan Zhang
Journal:  Cancer Biol Ther       Date:  2020-12-07       Impact factor: 4.742

4.  MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.

Authors:  Marco Perez; Juan M Praena-Fernandez; Blanca Felipe-Abrio; Maria A Lopez-Garcia; Antonio Lucena-Cacace; Angel Garcia; Matilde Lleonart; Guiovanna Roncador; Juan J Marin; Amancio Carnero
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

5.  MAP17, a ROS-dependent oncogene.

Authors:  Amancio Carnero
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

6.  The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.

Authors:  José M García-Heredia; Amancio Carnero
Journal:  Oncotarget       Date:  2017-10-06

Review 7.  Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases.

Authors:  José M García-Heredia; Amancio Carnero
Journal:  Mol Cancer       Date:  2018-04-12       Impact factor: 27.401

8.  Impaired in vitro erythropoiesis following deletion of the Scl (Tal1) +40 enhancer is largely compensated for in vivo despite a significant reduction in expression.

Authors:  Rita Ferreira; Dominik Spensberger; Yvonne Silber; Andrew Dimond; Juan Li; Anthony R Green; Berthold Göttgens
Journal:  Mol Cell Biol       Date:  2013-01-14       Impact factor: 4.272

9.  Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).

Authors:  Marco Perez; Javier Peinado-Serrano; Jose Manuel Garcia-Heredia; Irene Felipe-Abrio; Cristina Tous; Irene Ferrer; Javier Martin-Broto; Carmen Saez; Amancio Carnero
Journal:  Oncotarget       Date:  2016-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.